Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
OwnerAnthony H. Cincottainventor
Life of this patent
Estimating the term…
Abstract
Methods and compositions comprising one or more dopamine neuronal activity enhancers (e.g., dopamine receptor agonists), pantethine and solubilized curcumin for use in treating NAFLD and NASH are provided. Methods and compositions comprising one or more dopamine neuronal activity enhancers (e.g., dopamine receptor agonists), pantethine and solubilized curcumin for use in treating NAFLD and NASH are provided.
Claims21
-36. (canceled)
A method of treating non-alcoholic steatohepatitis (NASH) in a subject in need thereof, which comprises administering to a subject in need of such treatment a biological source of L-DOPA,-pantethine, and curcumin, said co-administration taking place between 0400 and 1200 hours.
A pharmaceutical dosage comprising a biological source of L-DOPA, pantethine and curcumin.
A method of treating metabolic disorders in a subject in need thereof which comprises co-administering to a subject in need of such treatment in a single formulation or separately (i) Mucuna pruriens containing L-DOPA, (ii) pantethine, and (ii) curcumin, said co-administration taking place within 4 hours of waking in the morning.
Dependencies are inferred from the claim text.